Abstract:Mitochondrial metabolism is essential for tumorigenesis, and the development of cancer is usually accompanied by alternations of mitochondrial function. Emerging studies have demonstrated that targeting mitochondria and mitochondrial metabolism is an effective strategy for cancer therapy. In this work, eight phosphorescent organometallic rhenium(I) complexes have been synthesized and explored as mitochondria-targeted theranostic agents, capable of inducing and tracking the therapeutic effect simultaneously. Complexes 1b-4b can quickly and efficiently penetrate into A549 cells, specifically localizing within mitochondria, and their cytotoxicity is superior to cisplatin against the cancer cells screened. Notably, complex 3b [Re(CO)3(DIP) (py-3-CH2Cl)]+ containing thiol-reactive chloromethylpyridyl moiety for mitochondria immobilization shows higher cytotoxicity and selectivity against cancer cells than other Re(I) complexes without mitochondria-immobilization properties. Mechanistic studies show that complexes 1b-4b induce a cascade of mitochondria-dependent events including mitochondrial damage, mitochondrial respiration inhibition, cellular ATP depletion, reactive oxygen species (ROS) elevation, and caspase-dependent apoptosis. By comparison, mitochondria-immobilized 3b causes more effective repression of mitochondrial metabolism than mitochondrial-nonimmobilized complexes. The excellent phosphorescence and O2-sensitive lifetimes of mitochondria-immobilized 3b can be utilized for real-time tracking of the morphological changes of mitochondria and mitochondrial respiration repression during therapy process, accordingly providing reliable information for understanding anticancer mechanisms.

Rational Design of Platinum(ii) Complexes with Orthogonally Oriented Triazolyl Ligand with Emission Enhancement Characteristics for Cancer Chemotherapy in Vivo

Towards the Rational Design of Platinum(ii) and Gold(iii) Complexes As Antitumour Agents

Triphenylphosphine-Modified Iridium III , Rhodium III , and Ruthenium II Complexes to Achieve Enhanced Anticancer Selectivity by Targeting Mitochondria

Phosphorescent Iridium(iii)-Bis-n-heterocyclic Carbene Complexes As Mitochondria-Targeted Theranostic and Photodynamic Anticancer Agents.

Design, Synthesis, and Biological Features of Platinum(Ii) Complexes with Rigid Steric Hindrance

Rational Design of Multi-Targeting Ruthenium- and Platinum-Based Anticancer Complexes

Targeting cancer cell metabolism with mitochondria-immobilized phosphorescent cyclometalated iridium(iii) complexes.

Mitochondria-targeted Phosphorescent Cyclometalated Iridium(iii) Complexes: Synthesis, Characterization, and Anticancer Properties

Mitochondria-targeted Cyclometalated Iridium-Β-carboline Complexes As Potent Non-Small Cell Lung Cancer Therapeutic Agents

Simultaneously Inducing and Tracking Cancer Cell Metabolism Repression by Mitochondria-Immobilized Rhenium(I) Complex

Fluorinated cyclometalated iridium(iii) complexes as mitochondria-targeted theranostic anticancer agents.

Iminoamido chelated iridium(III) and ruthenium(II) anticancer complexes with mitochondria-targeting ability and potential to overcome cisplatin resistance

Impact of Mitochondrion-Targeting Group on the Reactivity and Cytostatic Pathway of Platinum(IV) Complexes.

Cyclometalated iridium(iii) N-heterocyclic carbene complexes as potential mitochondrial anticancer and photodynamic agents.

Cyclometalated Ir(III) Complexes as Mitochondria-Targeted Photodynamic Anticancer Agents

Designing a Mitochondria-Targeted Theranostic Cyclometalated Iridium(III) Complex: Overcoming Cisplatin Resistance and Inhibiting Tumor Metastasis through Necroptosis and Immune Response

Synthesis, invitro Cytotoxicity, and Interaction with DNA of Platinum(II) Complexes with N-Monocycloalkyl Derivatives of 1R,2R-Diaminocyclohexane as Carrier Ligands

Synthesis and in vitro Cytotoxicity of Platinum(Ⅱ) Complexes Chelated with Chiral N-monosubstituted 1,2-Cyclohexyldiamine Derivatives

Synthesis, Subcellular Localization and Anticancer Mechanism Studies of Unsymmetrical Iridium(III) Complexes

Fine-tuning the side-chain length of iridium(III) complexes for enhanced Photophysical properties in Cancer Theranostics

Synthesis and biological evaluation of new mono naphthalimide platinum(IV) derivatives as antitumor agents with dual DNA damage mechanism